$ZURA
+9% today, leading the PRISM Biotech Index ๐
Merck's HS data at #EADV2026 put the hidradenitis suppurativa field in focus, and Zura's 247-patient TibuSHIELD Phase 2 readout is due this quarter.
Full story ๐
prismmarketview.com/zura-bio-sha...
